Related Experiment Video
Updated: Mar 19, 2026
Chronic Salmonella Infected Mouse Model
Published on: May 31, 2010
Antimelanoma effect of Salmonella Typhimurium integration host factor mutant in murine model
Catierine Hirsch Werle1, Igor Damiani1, Guilherme Paier Milanez1
1Department of Genetics, Evolution & Bioagents, Institute of Biology, University of Campinas - UNICAMP, Campinas, São Paulo, Brazil.
Aim:
This study aimed to evaluate an attenuated Salmonella ihfA-null mutant strain as therapeutic agent to control tumor growth.
Materials & Methods:
After bacterial toxicity evaluation, C57BL/6JUnib mice were inoculated with B16F10 cells and treated with two Salmonella strains (LGBM 1.1 and LGBM 1.41).
Results:
LGBM 1.1 can reduce tumor mass, but it exerts some toxic effects. Although LGBM 1.41 is less toxic than LGBM 1.1, it does not reduce tumor mass significantly. Indeed, animals treated with LGBM 1.41 present only slightly initial delay in tumor progression and increased survival rate as compared with the control.
Conclusion:
The null-mutants of ihfA gene of Salmonella Typhimurium could be a promising candidate for melanoma treatment.
Insights
Attenuated Salmonella Typhimurium ihfA-null mutants show potential for melanoma treatment. One strain reduced tumor mass but caused toxicity, while another was less toxic but less effective in controlling tumor growth.
Area of Science:
- Oncology
- Microbiology
- Immunotherapy
Background:
- Cancer immunotherapy leverages biological agents to stimulate anti-tumor immune responses.
- Salmonella Typhimurium is an opportunistic pathogen that can be engineered for cancer therapy due to its tumor-homing properties.
- The ihfA gene is crucial for bacterial adaptation and survival, making its null mutants potential candidates for attenuated therapeutic strains.
Purpose of the Study:
- To evaluate the therapeutic potential of an attenuated Salmonella Typhimurium ihfA-null mutant strain for controlling tumor growth.
- To assess the efficacy and toxicity of two specific Salmonella strains, LGBM 1.1 and LGBM 1.41, in a murine melanoma model.
Main Methods:
- Bacterial toxicity was evaluated in vitro and in vivo.
- C57BL/6JUnib mice were inoculated with B16F10 melanoma cells.
- Tumor-bearing mice were treated with either LGBM 1.1 or LGBM 1.41 Salmonella strains.
Main Results:
- The LGBM 1.1 strain demonstrated a reduction in tumor mass but exhibited notable toxic effects.
- The LGBM 1.41 strain showed reduced toxicity compared to LGBM 1.1.
- LGBM 1.41 did not significantly reduce tumor mass, offering only a slight initial delay in tumor progression and a modest increase in survival rate.
Conclusions:
- Salmonella Typhimurium strains with an ihfA-null mutation represent a promising avenue for melanoma treatment.
- Further research is warranted to optimize Salmonella-based therapies for enhanced efficacy and safety in cancer treatment.
